Breaking News

Nestle Expands Skin Health Platform

May 28, 2014

To purchase key assets of Valeant Pharmaceutical for $1.4 billion.

Looks like Nestlé is serious about skin health. Today, the company said it will reinforce its newly-created Nestlé Skin Health unit with the the full rights to commercialize several key aesthetic dermatology products from Valeant Pharmaceuticals International. The $1.4 billion cash deal is for the US and Canada. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercialises the products included in this transaction outside those markets, according to Nestlé.

Under terms of the agreement, Nestlé is acquiring the full rights to commercialise in the US and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the US, Canada and many markets around the world.

“With this deal we have acquired key strategic assets to extend Nestlé’s activities in the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products,” said Nestlé Chairman Peter Brabeck-Letmathe.

“This move will reinforce Galderma’s leading position in the industry when it becomes Nestlé Skin Health by allowing it to complete its geographic footprint for its strong portfolio of brands and leading medical solutions globally,” said Nestlé Chief Executive Paul Bulcke.

The transaction is subject to regulatory approval and customary closing conditions.

Back in February,  Nestlé announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a broad range of innovative and scientifically-proven products. The foundation for the company would be Galderma, the 50/50 joint venture with L’Oréal, which would become fully-owned by Nestlé. Bübchen, Nestlé's existing infant skin care business, would be merged into the new entity.

The acquisition of Galderma is awaiting final regulatory clearance.

 

Related End-User Markets:

Related Raw Materials:

  • What’s Up with Brexit?

    What’s Up with Brexit?

    March 9, 2017
    During In-Cosmetics, industry experts from the CTPA will weigh in on what’s ahead for the beauty industry.

  • How We Clean

    How We Clean

    Tom Branna, Editorial Director||March 6, 2017
    Consumers describe what makes them tick and what ticks them off about household cleaning products.

  • Fit for Fitness

    Fit for Fitness

    Christine Esposito, Associate Editor||February 21, 2017
    Kinx Active is a new brand targeting women who want beauty products that can stand up to their fitness routines.

  • New Faces in Familiar Places

    New Faces in Familiar Places

    Tom Branna, Editorial Director||March 1, 2017
    The American Cleaning Institute officially welcomed its new president.

  • Special Delivery

    Special Delivery

    Tom Branna, Editorial Director||March 1, 2017
    UV protection is important, but what good is that sunscreen if consumers won’t apply it?

  • OTC = TLC

    OTC = TLC

    Christine Esposito, Associate Editor||March 1, 2017
    Over-the-counter treatments provide consumers’ skin and hair with extra care.